The Kinetix Group-Powered by Petauri™

Big news! 📣 The Kinetix Group (TKG) has been recognized as an MM+M Market Access Agency of the Year finalist! The MM+M Awards recognizes, champions, and celebrates creativity and effectiveness in healthcare marketing and communications. Winners of Market Access Agency of the Year and other awards will be announced at the MM+M Awards gala on October 10. To learn more about this recognition, visit here > https://lnkd.in/ddtDtjUC #TheKinetixGroup #MMMAwards #deeplyinformed #trustedtodeliver

The topic for this week’s The Kinetix Group PACT Executive Briefing is an “Introduction to Targeted Therapies: CAR T-cell Therapy.” T-cell Transfer Therapy is a special type of immunotherapy that takes a person’s own T-cells (a type of immune cell), adds specific antigens to the T-cells that can identify the cancer cells, and puts them back into the person’s body. Cancer cells express unique antigens (signaling proteins). T-cells are programmed in the lab to find those signals and deliver a cancer stopping treatment right to the individual cancer cell. There are two main types of T-cell transfer therapy: tumor-infiltrating lymphocytes (TIL) and CAR T-cell Therapy. Need more information? As always, if you need a deeper dive into any of these topics, please don’t hesitate to reach out. Check out The Kinetix Group‘s growing library of TKG PACT Executive Briefings where you can listen and download the companion PDF infographics. https://lnkd.in/evZKhgre #Market_Access, #TKG, #TKGPACT, #Petauri, #CAR_Tcell_Therapy, #CAR_T, #Immunotherapy, #Targeted_Therapy, #Specialty_Pharmacy, #Medication, #Cancer

The Kinetix Group (TKG) hopes everyone enjoyed a restful summer and Labor Day weekend. We look forward to connecting with you again in the fall!

We're excited to announce that Petauri™ now boasts a team of over 360 talented professionals, all dedicated to speeding healthcare innovations to the patients who need them. As we continue to expand and innovate, we're committed to driving positive change and making an impact in the healthcare landscape. Want to learn more about our rapid growth trajectory and how we're making a difference? Contact us at https://lnkd.in/ebCSBH8b #Healthcare #MarketAccess #MedicalAffairs #HealthcareTransformation

The topic for this week’s The Kinetix Group PACT Executive Briefing is “Provider Insights on the Impact of 340B Pricing.” We frequently get asked for insights on how the 340B Drug Pricing Program may... or may not... be impacting the prescribing choices of participating covered entities. The Health Resources and Services Administration (HRSA) administers this federal program which is intended to help safety-net providers carry out their missions to serve their communities. The Kinetix Group (TKG) recently conducted a market access research study to gain insights from healthcare providers on how the 340B program is impacting care delivery in covered entities. You can reach out to us for the full study, but a few of the highlights from our study are included in this week’s Executive Briefing. Need more information? As always, if you need a deeper dive into any of these topics, please don’t hesitate to reach out. Check out The Kinetix Group‘s growing library of TKG PACT Executive Briefings where you can listen and download the companion PDF infographics. https://lnkd.in/evZKhgre #Market_Access, #TKG, #TKGPACT, #340B, #Pharmacy, #Specialty_Pharmacy, #Medication

As summer slowly winds to a close, we have been reminiscing about all the good times with TKG employees. ⛱️ See some of our favorite event highlights below! 🏕️ Summer Camp Craft Hour 🥇 Summer Olympics Watch Party #culture #camp #SummerOlympics

Great opportunity for our global partners to learn about the constantly evolving healthcare landscape in the UK with our colleagues at Mtech Access!

The topic for this week’s The Kinetix Group PACT Executive Briefing is “The Federal NOPAIN Act.” The Federal “Non-Opioids Prevent Addiction In the Nation Act” (or, the “NOPAIN Act”), Senate bill S.586, was signed into law in December 2022. It takes effect this coming January as part of the Centers for Medicare and Medicaid Services 2025 OPPS proposed rule. The NOPAIN Act directs CMS to reimburse hospital and surgical centers separately for non-opioid, post-surgical pain control, in hopes of reducing or replacing opioid consumption. By separating, or “unbundling,” payment for non-opioid pain control, hospitals and surgical centers may receive additional reimbursement for non-opioid alternatives, encouraging the use of substitute means of pain control. This helps to ensure that non-opioid options are more widely available to individuals as a post-surgical treatment option. The goal is to reduce the number of excess opioid pills available within communities, decrease the misuse of opioids, and ultimately reduce opioid-related deaths in the U.S. The NOPAIN Act also increases access to other therapies for pain control, to encourage greater use of non-opioid alternatives. Sadly, the misuse of opioids has had a devastating impact on our country. • 3 out of every 4 deaths from a drug-related overdose in 2022 involved opioids. • Over 500,000 people died from an opioid-related overdose from 1999 to 2020. • The opioid epidemic cost the US nearly $1.5 trillion dollars in 2020 alone – up 37% from 2017. The NOPAIN Act ensures patients and providers have greater choices in pain management options and supports broader efforts to combat the deadly effects of the opioid epidemic. Need more information? As always, if you need a deeper dive into any of these topics, please don’t hesitate to reach out. Check out The Kinetix Group‘s growing library of TKG PACT Executive Briefings where you can listen and download the companion PDF infographics. https://lnkd.in/evZKhgre #Market_Access, #TKG, #TKGPACT, #Opioid, #NOPAIN_Act, #NOPAIN, #NonOpioid, #Pharmacy, #Specialty_Pharmacy, #Medication

Welcome to TKG’s Market Access Insights Quarterly! Our quarterly newsletter offers market access-focused industry insights from thought leaders, decision-makers and customers. This edition's topics include: - Patient Bagging - CMS Prior Authorization Final Rule - No Surprises Act The Kinetix Group (TKG) can be your strategic partner in navigating the increasingly complex healthcare landscape. Access our growing insights library here > https://lnkd.in/d2WQWP2C Send topic suggestions or questions by emailing [email protected]

TKG’s Brain Health Leaders Network (BHLN) is proud to be a facilitator of the Alzheimer’s Disease Biomarkers Task Force, whose poster will be presented at the Alzheimer's Association® International Conference this week.    Soo Borson MD, member of the Alzheimer’s Disease Biomarkers Task Force and co-lead of the BOLD Center on Early Detection of Dementia at NYU Langone, will present “Implementing a biomarker-enabled care pathway to accelerate identification of early-stage Alzheimer’s disease in primary care” today at 3:30 p.m. at Exhibit Hall BC (poster number: Tuesday-880).   This work was made possible by support from Novo Nordisk.   To learn more about other BHLN initiatives, please visit https://lnkd.in/eQkfsYgK    BHLN is part of TKG's Networks of Excellence. Discover how these networks are helping to advance care delivery here > https://lnkd.in/e2bzP6eT   #BHLN #AAIC2024 #biomarkers #Alzheimers #primarycare